Discovery of Novel Tubulin Inhibitors via Structure-Based Hierarchical Virtual Screening
暂无分享,去创建一个
Yanli Wang | Ran Cao | Minyu Liu | Min Yin | Quanhai Liu | Niu Huang | Yanli Wang | M. Yin | R. Cao | Quanhai Liu | Minyu Liu | Niu Huang
[1] W. Waud,et al. Comparison of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines) with several other inhibitors of mitosis. , 1987, Cancer research.
[2] Jan Balzarini,et al. Synthesis and cellular pharmacology studies of a series of 2-amino-3-aroyl-4-substituted thiophene derivatives. , 2010, Medicinal chemistry (Shariqah (United Arab Emirates)).
[3] B. Shoichet,et al. A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.
[4] B. Shoichet,et al. Hierarchical docking of databases of multiple ligand conformations. , 2005, Current topics in medicinal chemistry.
[5] H. Hsieh,et al. Pharmaceutical design of antimitotic agents based on combretastatins. , 2005, Current pharmaceutical design.
[6] Carlos Alfonso,et al. Stathmin and Interfacial Microtubule Inhibitors Recognize a Naturally Curved Conformation of Tubulin Dimers* , 2010, The Journal of Biological Chemistry.
[7] I. Barasoain,et al. Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863. , 1994, Cancer research.
[8] Ray Luo,et al. Accelerated Poisson–Boltzmann calculations for static and dynamic systems , 2002, J. Comput. Chem..
[9] Chryso Kanthou,et al. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies , 2009, International journal of experimental pathology.
[10] Anurag Chaudhary,et al. Combretastatin a-4 analogs as anticancer agents. , 2007, Mini reviews in medicinal chemistry.
[11] Ki Young Lee,et al. Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. , 2006, Journal of medicinal chemistry.
[12] I. Kuntz,et al. The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[13] P A Kollman,et al. Continuum solvent studies of the stability of RNA hairpin loops and helices. , 1998, Journal of biomolecular structure & dynamics.
[14] P. Kollman,et al. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? , 2000 .
[15] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[16] Andrea Brancale,et al. The Tubulin Colchicine Domain: a Molecular Modeling Perspective , 2012, ChemMedChem.
[17] M. Jacobson,et al. Molecular mechanics methods for predicting protein-ligand binding. , 2006, Physical chemistry chemical physics : PCCP.
[18] A. Yamaguchi,et al. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. , 1997, Cancer research.
[19] E Hamel,et al. The synthesis and tubulin binding activity of thiophene-based analogues of combretastatin A-4. , 2001, Bioorganic & medicinal chemistry letters.
[20] Li Qian,et al. Binding Orientations, QSAR, and Molecular Design of Thiophene Derivative Inhibitors , 2009, Chemical biology & drug design.
[21] D. Zaharevitz,et al. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. , 2005, Journal of medicinal chemistry.
[22] V. Peyrot,et al. Tubulin binding of two 1-deaza-7,8-dihydropteridines with different biological properties: enantiomers NSC 613862 (S)-(-) and NSC 613863 (R)-(+). , 1993, Biochemistry.
[23] Gisbert Schneider,et al. Virtual screening: an endless staircase? , 2010, Nature Reviews Drug Discovery.
[24] I. Kuntz,et al. Automated docking with grid‐based energy evaluation , 1992 .
[25] M. L. Connolly. Solvent-accessible surfaces of proteins and nucleic acids. , 1983, Science.
[26] B. Honig,et al. A rapid finite difference algorithm, utilizing successive over‐relaxation to solve the Poisson–Boltzmann equation , 1991 .
[27] Nikolay V. Dokholyan,et al. Cheminformatics Meets Molecular Mechanics: A Combined Application of Knowledge-Based Pose Scoring and Physical Force Field-Based Hit Scoring Functions Improves the Accuracy of Structure-Based Virtual Screening , 2012, J. Chem. Inf. Model..
[28] Conrad C. Huang,et al. The MIDAS display system , 1988 .
[29] Ping-Chiang Lyu,et al. Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity. , 2009, Journal of medicinal chemistry.
[30] R. Friesner,et al. Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .
[31] Brian K. Shoichet,et al. ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..
[32] Brian K. Shoichet,et al. Rapid Context-Dependent Ligand Desolvation in Molecular Docking , 2010, J. Chem. Inf. Model..
[33] Chryso Kanthou,et al. Disrupting tumour blood vessels , 2005, Nature Reviews Cancer.
[34] B. Matthews,et al. A model binding site for testing scoring functions in molecular docking. , 2002, Journal of molecular biology.
[35] Raimond B G Ravelli,et al. Variations in the colchicine-binding domain provide insight into the structural switch of tubulin , 2009, Proceedings of the National Academy of Sciences.
[36] R. D'Amato,et al. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[37] M. Jacobson,et al. Binding-Site Assessment by Virtual Fragment Screening , 2010, PloS one.
[38] Niu Huang,et al. Physics-Based Scoring of Protein-Ligand Complexes: Enrichment of Known Inhibitors in Large-Scale Virtual Screening , 2006, J. Chem. Inf. Model..
[39] S Seeber,et al. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. , 2001, Cancer research.
[40] Jing Chen,et al. Recent development and SAR analysis of colchicine binding site inhibitors. , 2009, Mini reviews in medicinal chemistry.
[41] J M Blaney,et al. A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.
[42] B. Honig,et al. A hierarchical approach to all‐atom protein loop prediction , 2004, Proteins.
[43] R. Friesner,et al. High‐resolution prediction of protein helix positions and orientations , 2004, Proteins.
[44] Jan Balzarini,et al. Synthesis of novel antimitotic agents based on 2-amino-3-aroyl-5-(hetero)arylethynyl thiophene derivatives. , 2011, Bioorganic & Medicinal Chemistry Letters.
[45] Nikolay V. Dokholyan,et al. Combined Application of Cheminformatics- and Physical Force Field-Based Scoring Functions Improves Binding Affinity Prediction for CSAR Data Sets , 2011, J. Chem. Inf. Model..
[46] Dulal Panda,et al. Microtubule assembly dynamics: An attractive target for anticancer drugs , 2008, IUBMB life.
[47] Junmei Wang,et al. Development and testing of a general amber force field , 2004, J. Comput. Chem..
[48] J. Jaén,et al. Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[49] M. Castoldi,et al. Purification of brain tubulin through two cycles of polymerization-depolymerization in a high-molarity buffer. , 2003, Protein expression and purification.
[50] Alberto Massarotti,et al. Identification of Novel Antitubulin Agents by Using a Virtual Screening Approach Based on a 7‐Point Pharmacophore Model of the Tubulin Colchi‐Site , 2011, Chemical biology & drug design.
[51] Anke Wienecke,et al. Indibulin, a novel microtubule inhibitor, discriminates between mature neuronal and nonneuronal tubulin. , 2009, Cancer research.
[52] K. Sharp,et al. Accurate Calculation of Hydration Free Energies Using Macroscopic Solvent Models , 1994 .
[53] Patrick A. Curmi,et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain , 2004, Nature.
[54] Young Hoon Kim,et al. Structure-based virtual screening of novel tubulin inhibitors and their characterization as anti-mitotic agents. , 2010, Bioorganic & medicinal chemistry.
[55] Brian K. Shoichet,et al. Virtual screening of chemical libraries , 2004, Nature.
[56] F. Giles,et al. Microtubule dynamics as a target in oncology. , 2009, Cancer treatment reviews.
[57] W. L. Jorgensen,et al. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .
[58] M. Kavallaris. Microtubules and resistance to tubulin-binding agents , 2010, Nature Reviews. Cancer.
[59] Giovanni Sorba,et al. Medicinal chemistry of combretastatin A4: present and future directions. , 2006, Journal of medicinal chemistry.
[60] M. Jordan,et al. Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.
[61] George A. Kaminski,et al. Force Field Validation Using Protein Side Chain Prediction , 2002 .
[62] Mathias Schmidt,et al. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[63] Giuseppe Basso,et al. Synthesis and biological evaluation of 2-(3',4',5'-trimethoxybenzoyl)-3-aryl/arylaminobenzo[b]thiophene derivatives as a novel class of antiproliferative agents. , 2010, European journal of medicinal chemistry.
[64] C. Dumontet,et al. Microtubule-binding agents: a dynamic field of cancer therapeutics , 2010, Nature Reviews Drug Discovery.